Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V5NZ
|
|||
| Former ID |
DNC008568
|
|||
| Drug Name |
5'-(N-ethyl-N-isopropyl)amiloride
|
|||
| Synonyms |
EIPA; 5-(N-Ethyl-N-isopropyl)amiloride; 1154-25-2; Ethylisopropylamiloride; 5-(Ethylisopropyl)amiloride; Ethyl isopropyl amiloride; 5-(N-ethyl-N-isopropyl)-Amiloride; 3-Amino-N-(aminoiminomethyl)-6-chloro-5-[ethyl(1-methylethyl)amino]-2-pyrazinecarboxamide; N-Amidino-3-amino-5-ethylisopropylamino-6-chloropyrazine carboxamide; C11H18ClN7O; CHEMBL517986; 5-(N-Ethyl-N-isopropyl) Amiloride; 3-Amino-N-(aminoiminomethyl)-6-chloro-5-(ethyl(1-methylethyl)amino)pyrazinecarboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H18ClN7O
|
|||
| Canonical SMILES |
CCN(C1=NC(=C(N=C1Cl)C(=O)N=C(N)N)N)C(C)C
|
|||
| InChI |
1S/C11H18ClN7O/c1-4-19(5(2)3)9-7(12)16-6(8(13)17-9)10(20)18-11(14)15/h5H,4H2,1-3H3,(H2,13,17)(H4,14,15,18,20)
|
|||
| InChIKey |
QDERNBXNXJCIQK-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1154-25-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
5244803, 6301618, 8151289, 11110726, 14800448, 17404609, 24278223, 24717463, 29220994, 46500378, 48244490, 48478657, 50064198, 50105766, 50105767, 50534987, 53777151, 53788393, 57321028, 71822512, 85085989, 85230902, 90341436, 91702910, 92303589, 103128718, 103639263, 104115393, 104298743, 117559334, 118048142, 121360975, 124546094, 124749401, 124801073, 124879145, 124879146, 126407194, 129005905, 134345773, 135061498, 139681126, 142677707, 152163695, 162092157, 162262753, 163131464, 163563999, 164787181, 165230482
|
|||
| ChEBI ID |
CHEBI:136538
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium/hydrogen exchanger 1 (SLC9A1) | Target Info | Inhibitor | [2] |
| KEGG Pathway | cAMP signaling pathway | |||
| Cardiac muscle contraction | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Regulation of actin cytoskeleton | ||||
| Thyroid hormone signaling pathway | ||||
| Salivary secretion | ||||
| Gastric acid secretion | ||||
| Pancreatic secretion | ||||
| Bile secretion | ||||
| Proteoglycans in cancer | ||||
| Pathway Interaction Database | Endothelins | |||
| RhoA signaling pathway | ||||
| ErbB1 downstream signaling | ||||
| Signaling mediated by p38-alpha and p38-beta | ||||
| Reactome | Hyaluronan uptake and degradation | |||
| WikiPathways | Regulation of Actin Cytoskeleton | |||
| G Protein Signaling Pathways | ||||
| Glycosaminoglycan metabolism | ||||
| Osteoclast Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4186). | |||
| REF 2 | NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous ... J Biol Chem. 2007 Jul 6;282(27):19716-27. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.